Free tool
FAERS Monitor: Jaypirca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216059 or its brand name (Jaypirca, Pirtobrutinib). Reports on generic versions are filed under their own applications.
Reports
980
Serious
680
69% of reports
Hospitalization
283
Death reported
232
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death120
- malignant neoplasm progression88
- pneumonia74
- off label use70
- disease progression64
- splenomegaly44
- chronic lymphocytic leukaemia41
- anaemia37
- drug ineffective35
- pancytopenia35
- lymphadenopathy33
- white blood cell count increased31
- cytokine release syndrome29
- platelet count decreased28
- tumour lysis syndrome28
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 17 |
| 2023 | 117 |
| 2024 | 173 |
| 2025 | 286 |
| 2026 | 387 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,179 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic lymphocytic leukaemiaSignal | 41 | 187.1 | 138.5 | 7,341 |
| splenomegalySignal | 44 | 80.9 | 60.5 | 3,380 |
| tumour lysis syndromeSignal | 28 | 68.5 | 47.5 | 1,791 |
| cytokine release syndromeSignal | 29 | 31.1 | 21.7 | 814 |
| lymphadenopathySignal | 33 | 20.0 | 14.3 | 578 |
| malignant neoplasm progressionSignal | 88 | 18.5 | 15.1 | 1,441 |
| white blood cell count increasedSignal | 31 | 17.4 | 12.3 | 462 |
| pancytopeniaSignal | 35 | 13.4 | 9.7 | 392 |
| disease progressionSignal | 64 | 11.6 | 9.2 | 613 |
| platelet count decreasedSignal | 28 | 5.6 | 3.9 | 103 |
| pneumoniaSignal | 74 | 4.9 | 3.9 | 230 |
| anaemiaSignal | 37 | 4.2 | 3.0 | 87 |
| deathSignal | 120 | 3.0 | 2.5 | 164 |
| off label use | 70 | 1.7 | 1.4 | 21 |
| drug ineffective | 35 | 0.6 | 0.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.